Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: Analysis of long-term clinical outcomes

Lucia Pantani, Elena Zamagni, Beatrice Anna Zannetti, Annalisa Pezzi, Paola Tacchetti, Annamaria Brioli, Katia Mancuso, Giulia Perrone, Serena Rocchi, Patrizia Tosi, Michele Cavo

Research output: Contribution to journalArticle

Abstract

Bortezomib (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM). This retrospective study investigated the combination of bort (1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks) and dex (20 mg on the day of and the day after bort) as salvage treatment in 85 patients with R/R MM after prior autologous stem cell transplantation or conventional chemotherapy. The median number of prior lines of therapy was 2. Eighty-seven percent of the patients had received immunomodulatory drugs included in some line of therapy before bort-dex. The median number of bort-dex cycles was 6, up to a maximum of 12 cycles. On an intention-to-treat basis, 55 % of the patients achieved at least partial response, including 19 % CR and 35 % achieved at least very good partial response. Median durations of response, time to next therapy and treatment-free interval were 8, 11.2, and 5.1 months, respectively. The most relevant adverse event was peripheral neuropathy, which occurred in 78 % of the patients (grade II, 38 %; grade III, 21 %) and led to treatment discontinuation in 6 %. With a median follow up of 22 months, median time to progression, progression-free survival (PFS) and overall survival (OS) were 8.9, 8.7, and 22 months, respectively. Prolonged PFS and OS were observed in patients achieving CR and receiving bort-dex a single line of prior therapy. Bort-dex was an effective salvage treatment for MM patients, particularly for those in first relapse.

Original languageEnglish
Pages (from-to)123-128
Number of pages6
JournalAnnals of Hematology
Volume93
Issue number1
DOIs
Publication statusPublished - Jan 2014

Keywords

  • Bortezomib
  • Complete remission
  • Multiple myeloma
  • Peripheral neuropathy
  • Relapse
  • Treatment-free interval

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: Analysis of long-term clinical outcomes'. Together they form a unique fingerprint.

  • Cite this

    Pantani, L., Zamagni, E., Zannetti, B. A., Pezzi, A., Tacchetti, P., Brioli, A., Mancuso, K., Perrone, G., Rocchi, S., Tosi, P., & Cavo, M. (2014). Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: Analysis of long-term clinical outcomes. Annals of Hematology, 93(1), 123-128. https://doi.org/10.1007/s00277-013-1828-8